Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for ...

Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as ...